GlassScriptPhysician profile
Frank G Ditz
NPI 1184704124
$40,815.82
in general payments reported to CMS, 2019-2025
40 companies · $2,047 in 2025
The $2,047 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $1,031 · 2021: $1,282 · 2022: $1,262 · 2023: $25K · 2024: $8,392 · 2025: $2,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $6,486 · Travel and Lodging: $2,216 · Education: $4.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,052.20 |
| Food and Beverage | $6,485.93 |
| Travel and Lodging | $2,216.34 |
| Education | $4.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $30,575.38 | 2022-2024 | Quviviq |
| Novo Nordisk INC | $1,531.35 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,371.99 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $1,084.28 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $906.21 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Amarin Pharma, INC. | $668.96 | 2019-2023 | |
| Pfizer INC. | $627.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $555.16 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Esperion Therapeutics, INC. | $363.31 | 2024-2025 | Nexletol, Nexlizet |
| Amgen INC. | $269.06 | 2021-2024 | Otezla, Repatha |
| Galderma Laboratories, L.P. | $253.72 | 2019-2024 | Dysport |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.55 | 2019-2025 | Xifaxan, Trulance |
| Radius Health, INC. | $217.86 | 2019 | |
| Corcept Therapeutics | $206.27 | 2025 | Korlym |
| Exact Sciences Corporation | $182.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Ditz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.